Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Germline Genetics and Childhood Cancer: Emerging Cancer Predisposition Syndromes and Psychosocial Impacts.

Mitchell SG, Pencheva B, Porter CC.

Curr Oncol Rep. 2019 Aug 15;21(10):85. doi: 10.1007/s11912-019-0836-9. Review.

PMID:
31414239
2.

ETV6-related thrombocytopenia and leukemia predisposition.

Di Paola J, Porter CC.

Blood. 2019 Aug 22;134(8):663-667. doi: 10.1182/blood.2019852418. Epub 2019 Jun 27. Review.

PMID:
31248877
3.

Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?

Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols KE.

J Clin Oncol. 2019 Aug 20;37(24):2098-2104. doi: 10.1200/JCO.19.00181. Epub 2019 Jun 6. No abstract available.

PMID:
31170028
4.

IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.

Rabe JL, Gardner L, Hunter R, Fonseca JA, Dougan J, Gearheart CM, Leibowitz MS, Lee-Miller C, Baturin D, Fosmire SP, Zelasko SE, Jones CL, Slansky JE, Rupji M, Dwivedi B, Henry CJ, Porter CC.

Cancer Res. 2019 Jul 15;79(14):3702-3713. doi: 10.1158/0008-5472.CAN-18-3800. Epub 2019 May 29.

PMID:
31142509
5.

Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.

Hart MR, Anderson DJ, Porter CC, Neff T, Levin M, Horwitz MS.

PLoS Genet. 2018 Sep 14;14(9):e1007642. doi: 10.1371/journal.pgen.1007642. eCollection 2018 Sep.

6.

Macrocytic anemia in Lesch-Nyhan disease and its variants.

Cakmakli HF, Torres RJ, Menendez A, Yalcin-Cakmakli G, Porter CC, Puig JG, Jinnah HA.

Genet Med. 2019 Feb;21(2):353-360. doi: 10.1038/s41436-018-0053-1. Epub 2018 Jun 6.

7.

The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?

Felton KEA, Porter CC, Yang JJ.

Expert Rev Precis Med Drug Dev. 2018;3(6):339-341. doi: 10.1080/23808993.2018.1517026. Epub 2018 Sep 3. No abstract available.

8.

Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.

Garcia TB, Fosmire SP, Porter CC.

Leuk Res. 2018 Jan;64:30-33. doi: 10.1016/j.leukres.2017.11.004. Epub 2017 Nov 11.

9.

IFN-γ alters the expression of diverse immunity related genes in a cell culture model designed to represent maturing neutrophils.

Ellison MA, Gearheart CM, Porter CC, Ambruso DR.

PLoS One. 2017 Oct 5;12(10):e0185956. doi: 10.1371/journal.pone.0185956. eCollection 2017.

10.

Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Kalish JM, Doros L, Helman LJ, Hennekam RC, Kuiper RP, Maas SM, Maher ER, Nichols KE, Plon SE, Porter CC, Rednam S, Schultz KAP, States LJ, Tomlinson GE, Zelley K, Druley TE.

Clin Cancer Res. 2017 Jul 1;23(13):e115-e122. doi: 10.1158/1078-0432.CCR-17-0710. Review.

11.

Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood.

Achatz MI, Porter CC, Brugières L, Druker H, Frebourg T, Foulkes WD, Kratz CP, Kuiper RP, Hansford JR, Hernandez HS, Nathanson KL, Kohlmann WK, Doros L, Onel K, Schneider KW, Scollon SR, Tabori U, Tomlinson GE, Evans DGR, Plon SE.

Clin Cancer Res. 2017 Jul 1;23(13):e107-e114. doi: 10.1158/1078-0432.CCR-17-0790. Review.

12.

A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.

Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC.

Mol Cancer Ther. 2017 Oct;16(10):2058-2068. doi: 10.1158/1535-7163.MCT-16-0660. Epub 2017 Jun 27.

13.

Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders.

Walsh MF, Chang VY, Kohlmann WK, Scott HS, Cunniff C, Bourdeaut F, Molenaar JJ, Porter CC, Sandlund JT, Plon SE, Wang LL, Savage SA.

Clin Cancer Res. 2017 Jun 1;23(11):e23-e31. doi: 10.1158/1078-0432.CCR-17-0465. Review.

14.

Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions.

Porter CC, Druley TE, Erez A, Kuiper RP, Onel K, Schiffman JD, Wolfe Schneider K, Scollon SR, Scott HS, Strong LC, Walsh MF, Nichols KE.

Clin Cancer Res. 2017 Jun 1;23(11):e14-e22. doi: 10.1158/1078-0432.CCR-17-0428. Review.

15.

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.

Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL.

Mol Cancer Res. 2017 Apr;15(4):382-394. doi: 10.1158/1541-7786.MCR-16-0234. Epub 2017 Jan 20.

16.

Germ line mutations associated with leukemias.

Porter CC.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):302-308. Review.

17.

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.

Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR.

Oncotarget. 2016 Mar 29;7(13):15757-71. doi: 10.18632/oncotarget.7462.

18.

AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.

Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC.

Oncotarget. 2015 Sep 29;6(29):28001-10. doi: 10.18632/oncotarget.4830.

19.

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL.

Blood. 2015 Nov 5;126(19):2202-12. doi: 10.1182/blood-2015-04-639138. Epub 2015 Aug 31.

20.

INF-γ Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself.

Ellison MA, Thurman G, Gearheart CM, Seewald RH, Porter CC, Ambruso DR.

PLoS One. 2015 Aug 28;10(8):e0136766. doi: 10.1371/journal.pone.0136766. eCollection 2015.

21.

ETV6 mutations define a new cancer predisposition syndrome.

Kirkpatrick G, Noetzli L, Di Paola J, Porter CC.

Oncotarget. 2015 Jul 10;6(19):16830-1. No abstract available.

22.

Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.

Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, Rajpurkar M, Jones K, Gowan K, Balduini C, Pecci A, Gnan C, De Rocco D, Doubek M, Li L, Lu L, Leung R, Landolt-Marticorena C, Hunger S, Heller P, Gutierrez-Hartmann A, Xiayuan L, Pluthero FG, Rowley JW, Weyrich AS, Kahr WHA, Porter CC, Di Paola J.

Nat Genet. 2015 May;47(5):535-538. doi: 10.1038/ng.3253. Epub 2015 Mar 25.

23.

Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.

Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC.

Am J Hematol. 2014 Sep;89(9):896-903. doi: 10.1002/ajh.23776. Epub 2014 Jun 19.

24.

STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious.

Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A.

Cancer Res. 2014 May 1;74(9):2579-90. doi: 10.1158/0008-5472.CAN-13-3470. Epub 2014 Mar 3.

25.

Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.

Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC.

Mol Cancer Ther. 2013 Dec;12(12):2675-84. doi: 10.1158/1535-7163.MCT-13-0424. Epub 2013 Oct 11.

26.

Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells.

Choudhary R, Baturin D, Fosmire S, Freed B, Porter CC.

PLoS One. 2013;8(3):e59594. doi: 10.1371/journal.pone.0059594. Epub 2013 Mar 15.

27.

Targeting developmental pathways in children with cancer: what price success?

Gore L, DeGregori J, Porter CC.

Lancet Oncol. 2013 Feb;14(2):e70-8. doi: 10.1016/S1470-2045(12)70530-2. Review.

28.

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, DeGregori J.

Cancer Res. 2012 Aug 15;72(16):4154-64. doi: 10.1158/0008-5472.CAN-11-2848. Epub 2012 Jun 27.

29.

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.

Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM.

Nat Chem Biol. 2012 Jul;8(7):646-54. doi: 10.1038/nchembio.965. Epub 2012 Jun 3.

30.

Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.

Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J.

Leukemia. 2012 Jun;26(6):1266-76. doi: 10.1038/leu.2011.392. Epub 2012 Jan 13.

31.

Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities.

Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP.

Nature. 2012 Jan 22;482(7383):98-102. doi: 10.1038/nature10814.

32.

Relative fitness of hematopoietic progenitors influences leukemia progression.

Porter CC, Baturin D, Choudhary R, DeGregori J.

Leukemia. 2011 May;25(5):891-5. doi: 10.1038/leu.2011.22. Epub 2011 Feb 18. No abstract available.

33.

Irradiation selects for p53-deficient hematopoietic progenitors.

Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J.

PLoS Biol. 2010 Mar 2;8(3):e1000324. doi: 10.1371/journal.pbio.1000324.

34.

Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A.

Schlegel J, Redzic JS, Porter CC, Yurchenko V, Bukrinsky M, Labeikovsky W, Armstrong GS, Zhang F, Isern NG, DeGregori J, Hodges R, Eisenmesser EZ.

J Mol Biol. 2009 Aug 21;391(3):518-35. doi: 10.1016/j.jmb.2009.05.080. Epub 2009 Jun 3.

35.

Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.

Porter CC, Carver AE, Albano EA.

Pediatr Blood Cancer. 2009 Feb;52(2):298-300. doi: 10.1002/pbc.21786.

PMID:
18837430
36.

BCL6 expression correlates with monomorphic histology in children with posttransplantation lymphoproliferative disease.

Porter CC, Liang X, Gralla J, McGavran L, Albano EA.

J Pediatr Hematol Oncol. 2008 Sep;30(9):684-8. doi: 10.1097/MPH.0b013e31817eb7ca.

37.

Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection.

Porter CC, DeGregori J.

Blood. 2008 Dec 1;112(12):4466-74. doi: 10.1182/blood-2008-03-146571. Epub 2008 Jun 27.

38.

Posttransplant Hodgkin lymphoma preceded by polymorphic posttransplant lymphoproliferative disorder: report of a pediatric case and review of the literature.

Gheorghe G, Albano EA, Porter CC, McGavran L, Wei Q, Meltesen L, Danielson SM, Liang X.

J Pediatr Hematol Oncol. 2007 Feb;29(2):112-6.

PMID:
17279008
39.

Impaired DNA replication within progenitor cell pools promotes leukemogenesis.

Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J.

PLoS Biol. 2005 Dec;3(12):e401. Epub 2005 Nov 15.

40.

Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia.

Porter CC, Edwards KM, Zhu Y, Frangoul H.

Pediatr Blood Cancer. 2004 Jan;42(1):36-40.

PMID:
14752792
41.

Influenza immunization practices among pediatric oncologists.

Porter CC, Poehling KA, Hamilton R, Frangoul H, Cooper WO.

J Pediatr Hematol Oncol. 2003 Feb;25(2):134-8.

PMID:
12571465
42.
43.

Alpha 1B-adrenergic receptors in rat renal microvessels.

Canessa LM, Piccio MM, Vachvanichsanong P, Sidhu A, Porter CC, Robillard JE, Felder RA, Jose PA.

Kidney Int. 1995 Nov;48(5):1412-9.

44.

Ontogenic changes and regulation of renal angiotensin II type 1 receptor gene expression during fetal and newborn life.

Robillard JE, Schutte BC, Page WV, Fedderson JA, Porter CC, Segar JL.

Pediatr Res. 1994 Dec;36(6):755-62.

PMID:
7898984
45.

A new way to seal glass plates for denaturing gradient gel electrophoresis.

Kyllo JH, Kirby-Keyser L, Donohoue PA, Porter CC.

Biotechniques. 1994 May;16(5):792. No abstract available.

PMID:
8068325
46.

Developmental regulation of the alpha 1B-adrenoceptor in the sheep kidney.

Guillery EN, Porter CC, Page WV, Jose PA, Felder R, Robillard JE.

Pediatr Res. 1993 Aug;34(2):124-8.

PMID:
8233711
47.

Molecular studies of the fourth component of complement (C4) in glomerulonephritis.

McLean RH, Porter CC, Wyatt RJ.

Semin Nephrol. 1989 Mar;9(1):102-6. Review. No abstract available.

PMID:
2662294
48.

Hemolytic-uremic syndrome: a population-based study in Washington, DC and Baltimore, Maryland.

Kinney JS, Gross TP, Porter CC, Rogers MF, Schonberger LB, Hurwitz ES.

Am J Public Health. 1988 Jan;78(1):64-5.

49.

Pancreatic endocrine insufficiency in posttransplant cystinosis.

Fivush B, Green OC, Porter CC, Balfe JW, O'Regan S, Gahl WA.

Am J Dis Child. 1987 Oct;141(10):1087-9.

PMID:
3307383
50.

Accelerated recovery from immune-mediated thrombocytopenia with plasmapheresis.

Porter CC, Ruley EJ, Luban NL, Phillips TM, Bock GH, Salcedo JR, Fivush BA.

Am J Med. 1985 Dec;79(6):765-8.

PMID:
4073112

Supplemental Content

Loading ...
Support Center